Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:
“From ESMO advanced course on ADCs meet the new kids on the block:
- Bi-specific/Bi-paratopic ADCs
- PDCs with peptide masks allowing payload cleavage by tumor proteases
- ISACS with TLR or STING agonist payload
- DACs degrading target through proteasome ubiquitin.”
More posts featuring Giannis Mountzios on OncoDaily.
